Results 171 to 180 of about 5,364 (186)

Reduction of clozapine-induced hypersalivation by pirenzepine is safe.

Pharmacopsychiatry, 2004
B. Schneider, H. Weigmann, C. Hiemke, Bernhard Weber, Jürgen Fritze   +4 more
semanticscholar   +1 more source

CHOLINERGIC MUSCARINIC RECEPTOR BLOCKADE WITH PIRENZEPINE ABOLISHES SLOW WAVE SLEEP‐RELATED GROWTH HORMONE RELEASE IN NORMAL ADULT MALES

Clinical Endocrinology, 1986
J. Peters, P. Evans, M. Page, R. Hall, J. T. Gibbs, C. Diéguez, M. Scanlon   +6 more
semanticscholar   +1 more source

Prevention of form‐deprivation myopia with pirenzepine: a study of drug delivery and distribution

Ophthalmic & physiological optics, 1999
C. Cottriall, Neville A. McBrien, R. Annies, E. M. Leech   +3 more
semanticscholar   +1 more source

The Intact Human Neuroblastoma Cell (SH‐SY5Y) Exhibits High‐Affinity [3H]Pirenzepine Binding Associated with Hydrolysis of Phosphatidylinositols

Journal of Neurochemistry, 1988
M. Serra, L. Mei, W. Roeske, G. Lui, M. Watson, H. Yamamura   +5 more
semanticscholar   +1 more source

Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia

, 2009
L. Nelson
semanticscholar   +1 more source

Pirenzepine affects scleral metabolic changes in myopia through a non-toxic mechanism.

Experimental Eye Research, 2002
H. Truong, C. Cottriall, A. Gentle, N. Mcbrien   +3 more
semanticscholar   +1 more source

A rapid and versatile method to label receptor ligands using "click" chemistry: Validation with the muscarinic M1 antagonist pirenzepine.

Bioconjugate chemistry, 2006
D. Bonnet, B. Ilien, J. Galzi, Stéphanie Riché, Cyril Antheaune, M. Hibert   +5 more
semanticscholar   +1 more source

Muscarinic cholinergic receptor subtypes in human detrusor muscle studied by labeled and nonlabeled pirenzepine, AFDX-116 and 4DAMP.

Urologia internationalis, 1995
Shun Kondo, Takashi Morita, Yohtalou Tashima   +2 more
semanticscholar   +1 more source

In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.

Journal of Clinical Endocrinology and Metabolism, 1995
M. Maccario, Massimo Procopio, S. Grottoli, S. Oleandri, P. Razzore, F. Camanni, E. Ghigo   +6 more
semanticscholar   +1 more source

A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.

Life Science, 1983
M. Watson, H. Yamamura, W. Roeske
semanticscholar   +1 more source